Heart disease is the leading cause of illness and death in women, and four major medical groups now say care for it is too scattered to catch risk early.
The new material is two advisories published in Circulation in 2026: a presidential advisory and a science advisory. They come from the American Heart Association, the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine. These are expert guidance documents, not trials or studies that followed patients, so there are no participant numbers or measured outcomes. We had access only to the abstracts, so details beyond them are unverified.
According to the first advisory, heart risk in girls and women is underrecognized and underaddressed. That is especially true for exposure to sex hormones, which the authors call systemic modulators of cardiovascular biology. The abstract also says women see many specialists, including pediatrics, primary care, obstetrics and gynecology, cardiology and endocrinology, and that this fragments their care.
The groups propose a Female Life Stage framework. It defines four stages by changes in sex hormones: perimenarche, ovarian cycling, perimenopause and postmenopause. The advisory says these stages should inform screening, prevention and management of cardiovascular disease. The framework pairs hormonal, psychosocial and heart health rather than treating them separately.
For midlife, the STAT coverage adds detail. It reports that the guidance calls perimenopause a cardiovascular inflection point. It describes perimenopause as the transition of variable cycle length, skipped cycles and hormone changes, from about age 45 to 51. STAT reports that changes in cholesterol and metabolic health can be early signs of risk. Sadiya Khan, who chaired the writing group, told STAT: "Identifying risk early and acting on it may reduce risk of cardiovascular disease." The abstracts do not list specific tests or schedules, so what to check, and when, is a question for each person's clinician.
The second advisory looks at where this care would be delivered. It proposes national support for Comprehensive Centers of Excellence for Women's Cardiovascular Care. These would rest on four pillars: interdisciplinary clinical care, education and training, research, and community engagement. The authors say such centers can reduce fragmentation, support earlier risk identification and bring more women into clinical research. That is the authors' expectation. The abstract does not report results from any such center.
The limits matter. Advisories set out a rationale and priorities. They do not show that using the framework lowers heart attacks or deaths. The coverage's "may reduce" wording is Khan's, and it is a hope about early action rather than a tested result.
This differs from The Arising's October 18 report on ACOG's updated advice on hormone therapy for hot flashes. That piece dealt with treating symptoms. These advisories deal with spotting heart risk across life stages, and they are separate documents. Whether the framework is taken up in routine care, whether the proposed centers are built, and whether research shows that earlier attention in perimenopause changes heart outcomes.
Sources: Circulation (2026), STAT
Keep reading on this subject
Women’s midlife · Cardiovascular health